華潤雙鶴(600062.SH):子公司部分產品通過仿製藥質量和療效一致性評價及獲得藥品補充申請批准通知書
格隆匯5月12日丨華潤雙鶴(600062.SH)公佈,全資子公司安徽雙鶴藥業有限責任公司、控股子公司雙鶴天安藥業(貴州)股份有限公司分別收到了國家藥品監督管理局頒發的甘油果糖氯化鈉注射液《藥品補充申請批准通知書》和二甲雙胍恩格列淨片(I)《藥品補充申請批准通知書》。甘油果糖氯化鈉注射液是一種脱水藥,主要用於腦血管病、腦外傷、腦腫瘤、顱內炎症及其他原因引起的急慢性顱內壓增高,腦水腫等症。二甲雙胍恩格列淨片(I)配合飲食控制和運動,適用於正在接受恩格列淨和鹽酸二甲雙胍治療的2型糖尿病成人患者,用於改善這些患者的血糖控制。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.